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and post-year) retrospective cohort design, adherence of patients who enrolled in 
traditional managed care plans in the pre-year but changed to full replacement CDHPs 
in the post-year was compared to that of patients who continuously enrolled in tra-
ditional plan. Adherence was measured in four ways: 1) post-year continuation rate, 
and among continuous users; 2) gap between the last reﬁll of the pre-year and the ﬁrst 
reﬁll in the post-year; 3) change of compliance rate from the pre- to the post-year; 
and 4) total days with continuous drug supply in the post-year. Analysis was con-
ducted on eight drug classes: asthma, cardiac, diabetes, epilepsy, hypertension, hyper-
lipidemia, rheumatoid arthritis, and thyroid, that were identiﬁed from Speciﬁc 
Therapeutic Classiﬁcation code. RESULTS: CDHP patients had a slightly higher 
illness burden and used more medication in the pre-year. Continuation rate in the 
post-year was relatively high for all drug classes though the CDHP patients were less 
likely continue for cardiac and cholesterol drugs. Among continuous patients, CDHP 
patients took slightly longer to reﬁll their ﬁrst prescription in the post-year for four 
drug classes (4 days longer for cardiac and hypertension drugs, 5 days longer for 
cholesterol and 3 days longer for thyroid drugs). Compliance rate dropped overtime 
in both cohorts but the reduction was bigger among CDHP patients for three drug 
classes (adjusted ratio of odds ratios was 0.77, 0.78, 0.69 for asthma, cardiac, and 
cholesterol drugs, respectively). CDHP patients also terminated their continuous drug 
supply earlier (21 days earlier for epilepsy and 27 days earlier cholesterol drugs, 
respectively). CONCLUSIONS: Adherence was lower in a few drug classes among 
patients who enrolled in consumer-driven health plans.
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OBJECTIVES: To assess the medication usage behaviour of prescription drugs and 
study self medication behaviour in outdoor patients. METHODS: A prospective 
observational study was performed in outpatient pharmacy at a public teaching 
hospital in Northern India. Patients more than 18 years and who could speak, write 
or read Hindi or English were included. Hearing and visually disabled patients were 
excluded. The medication usage behaviour, drug knowledge, adherence to prescribed 
medication and self medication behaviour were assessed using a structured and vali-
dated questionnaire using Cronbach Alpha. RESULTS: A total of 160 patients were 
assessed. The median age was 38 years. The most common problems identiﬁed 
involved awareness about the name and frequency of the drugs prescribed (39%), 
discontinuation of the medication without consultation (38%), unaware of proper 
storage of medicines (48%), knowledge about allergies (32%), and side effects (18%) 
of the drugs prescribed. Interestingly, it was observed that 90% of the patients had 
an understanding of their disease(s) diagnosed. Patients maintained regular follow up 
with the physician (88%) and consulted physician/pharmacist in case of an unpleasant/ 
alarming drug effect (77%). Majority of the patients (61%) used ayurvedic/homeo-
pathic preparations in conjunction with prescribed allopathic medicines. More than 
three fourths of the patients (82%) self medicated using herbals and other dietary 
supplements for their illness. OTC medication use (85%) was seen for common indica-
tions such as fever, cough, headache and bodyache. CONCLUSIONS: Based upon 
these ﬁndings, it is clear that improvement in medication usage behaviour requires 
counseling to the patients in the identiﬁed areas.
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OBJECTIVES: We assessed the quality and characteristics of pharmacoeconomic 
evaluation submitted for reimbursement since Korean positive list system introduction. 
METHODS: Twenty-four submissions with pharmacoeconomic evaluation (PE) were 
included in this study, which are new medicines evaluated by Drug Beneﬁt Coverage 
Assessment Committee (DBCAC) from introduction of positive list system to June 30th 
in 2009. We evaluated them with HIRA PE checklist consisted of 21 items which 
was developed for assessing the appropriateness according to the guideline of phar-
macoeconomic evaluation in Korea and QHES checklist. RESULTS: Twenty-four 
submissions were categorized as Cost-Minimization analysis (n = 16, 66.6%), Cost-
Effectiveness analysis (n = 4, 16.7%) and Cost-Utility analysis (n = 4, 16.7%). On the 
average, 15 among 21 items of HIRA PE checklist were fulﬁlled (73%, range 
52.4∼100%) and quality assessment score by QHES was 62.1 (range 31–97). The 
items which submissions mostly followed were presenting analysis perspective, disag-
gregated incremental cost-effectiveness ratio, appropriate selection of primary 
outcome and discount rate of cost and effectiveness. The issues noted as inadequate 
submissions were obscure search process of cost and effectiveness data, cost estima-
tion, insufﬁcient examination of uncertainty and generalizability. The range of ICER 
per QALY (n = 4) was showed from 8K to 59K USD. DBCAC didn’t evaluate cost-
effectiveness with explicit threshold values and decisions considering ICER were made 
by deliberating on the uncertainty surrounding them as well as disease severity, societal 
burden, quality of life, and innovative nature of the medicine. CONCLUSIONS: This 
study could be helpful for understanding present state of pharmacoeconomic evalua-
tion submitted since the introduction of Korean positive list system and valuable for 
suggesting items required to be improved for appraisal.
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OBJECTIVES: The purpose of this analysis was to determine if integration of phar-
macy beneﬁts had an impact on the number of gaps in evidence-based care experienced 
by individuals and the number of gaps in care that those individuals close. METHODS: 
Database analysis was conducted on 262,000 individuals with coverage in 2008. 
Participants had to have 12 months of continuous enrollment in order to be included 
in the analysis. Matching on age, gender, and health risk was completed to partially 
adjust for differences between integrated and carve-out employers. A two-part regres-
sion model was then used to identify differences in the likelihood that individuals 
would adhere to evidence-based standards, and in the number of gaps in care that 
they would experience, while controlling for additional factors such as participation 
in outreach programs and plan design. RESULTS: Participants with integrated phar-
macy beneﬁts had a higher rate of gaps in care (Odds ratio 1.04, 95% ci 1.014–1.064), 
although the numbers of gaps experienced were lower (4.78 [95% ci 4.77–4.81] vs. 
4.87 [95% ci 4.85–4.89] in integrated plans vs. carve-out). While controlling for the 
initial number of open gaps, the likelihood of gap closure was higher in integrated 
plans than in carve-outs (Odds ratio 1.028 [95% ci 1.003–1.054]). The number of 
gaps closed was also higher (2.13 [95% ci 2.13–2.13] vs. 2.01 [95% ci 2.01–2.01] in 
integrated vs. carve-out). CONCLUSIONS: Higher rates of evidence-based gap closure 
are associated with individuals that participate in health plans with integrated phar-
macy beneﬁts when compared to individuals with carved-out plans.
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OBJECTIVES: Develop an essential medicines list (EML) in 2000 to improve rational 
use of medicines and contain costs in Middle East- Palestine. METHODS: We exam-
ined effects of the EML in the Palestinian health care public sector. We obtained data 
on prescription patterns for medicines from 3570 prescriptions given during outpatient 
visits in 17 health care facilities in the West Bank from 1997 to 2003. We analyzed 
the prescriptions to measure rational use. We modeled indicators of rational use as a 
function of the EML and 16 health center indicator variables. RESULTS: The 
EML was effective in shifting all prescribing indicators toward standard values. To 
improve rational medicine use, treatment protocols for the most common diseases and 
continuous education for medical staff is required. CONCLUSIONS: Treatment pro-
tocols that limit physicians’ prescription choices for the most common diseases are 
necessary to improve the rational use of medicines in any setting. We found that the 
prescribing indicators least affected were the number of medicines per encounter and 
antibiotics as a percent of all medicines prescribed. The most affected indicator was 
the injectable medicines as a percent of all prescribed medicines. While change in the 
use of injectable medicines may be related to changes in individual preferences, cultural 
beliefs and values, most of the patients were aware of the implementation of EML, 
since their medicines where changed and substituted with less expensive bioequivalent 
ones.
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BACKGROUND: Quantifying the value of pharmacist-provided services beyond dis-
pensing is imperative for the profession of pharmacy as it works to establish a baili-
wick within the evolving health care system. To date, the preponderance of research 
assessing the value of pharmacist-provided services takes a health care payer’s perspec-
tive. Less is known about the value consumers place on these services. The contingent 
valuation, or willingness-to-pay, method has been proposed as a technique to obtain 
consumer valuation of pharmacist-provided services. OBJECTIVES: The purpose of 
this research is to identify all published studies using the contingent valuation method 
to value pharmacist-provided services and evaluate those studies against published 
criteria for conducing contingent valuation surveys. METHODS: Relevant studies 
published in the English language were identiﬁed searching MEDLINE, ECONLIT 
and International Pharmaceutical Abstracts databases through December, 2008. Only 
studies that speciﬁcally elicited willingness-to-pay from actual or potential consumers 
of community pharmacist provided services were included. RESULTS: Twenty-three 
studies were identiﬁed using the search strategy outlined. Eighteen pharmacist-pro-
vided services were assessed in a variety of demographic and geographic populations. 
Studies were appraised using the 1993 NOAA panel recommendations for the contin-
gent valuation method. Not surprisingly, studies published before 1999 tended to use 
less standardized methods and typically did not conform to NOAA panel recommen-
dations, whereas those published after 1999 tended to have greater methodologic and 
statistical rigor. CONCLUSIONS: Surprisingly few published studies have employed 
the contingent valuation method to assess consumers’ perceptions of pharmacist-
provided services. Improving the quantity and quality of such studies will aid the 
profession in marketing pharmacy services to consumers. Understanding the pharmacy 
services that consumer’s value and their willingness-to-pay for those services will be 
